The United States has reported 7.1 million COVID-19 deaths. In 2020 alone, an estimated 10.9 million excess deaths worldwide were attributable to the pandemic.
Key Takeaways
- 10.9 million excess deaths in 2020 attributable to COVID-19 worldwide (IHME estimate for 2020 compared with expected baseline)
- 7.1 million COVID-19 deaths reported in the United States as of 2025-05-12 (CDC cumulative reported deaths)
- 4.9 million confirmed COVID-19 deaths reported globally as of 2025-05-12 (Our World in Data compiled cumulative confirmed deaths)
- Global COVID-19 vaccines market size reached $58.2 billion in 2023 (global market revenue for COVID-19 vaccines)
- BNT162b2 (Pfizer-BioNTech) had 95% efficacy against symptomatic COVID-19 in the phase 3 trial (published interim efficacy results)
- AstraZeneca’s AZD1222 trial reported 70.4% efficacy against symptomatic COVID-19 in certain analysis cohorts (phase 3 publication, COV0003/COV0022/other cohorts)
- In 2023, global COVID-19 related IT spending was $13.6 billion (IDC forecast for pandemic-response and remote-work/health IT initiatives)
- Telehealth usage increased by 154% in the week after COVID-19 stay-at-home orders compared with pre-pandemic baseline (CMS/industry utilization analysis)
- In 2021, 74% of organizations adopted some form of contactless technology for infection control (industry survey)
- Global GDP declined by 3.1% in 2020 due to COVID-19 (World Bank global economic prospects estimate)
- ILO estimated 2.7 billion people experienced reduced working hours in 2020 (ILO global estimate)
- International tourist arrivals fell by 74% in 2020 compared with 2019 (UNWTO/UN Tourism statistics)
- In 2020, total global healthcare spending increased by 9.6% due to COVID-19 response and care needs (OECD health spending analysis)
- A PCR test has a typical analytical limit of detection in the range of 10^1–10^3 copies/mL depending on assay design (peer-reviewed review on RT-PCR sensitivity)
- In a CDC evaluation, antigen tests had sensitivity of 72% (95% CI, 66%–77%) for detecting infection among symptomatic individuals and 58% (95% CI, 38%–74%) among asymptomatic individuals (systematic performance evaluation)
COVID-19 has driven huge mortality and ongoing health impacts, with Omicron dominating and vaccines and treatments reducing severity.
Related reading
01 · Category
Public Health Impact5 stats
01
10.9 million excess deaths in 2020 attributable to COVID-19 worldwide (IHME estimate for 2020 compared with expected baseline)
02
7.1 million COVID-19 deaths reported in the United States as of 2025-05-12 (CDC cumulative reported deaths)
03
4.9 million confirmed COVID-19 deaths reported globally as of 2025-05-12 (Our World in Data compiled cumulative confirmed deaths)
04
In 2022, global reported COVID-19 incidence fell by 84% compared with 2021 peak (WHO global trends analysis)
05
Omicron accounted for an estimated 97.5% of sequenced SARS-CoV-2 samples in the United States during the Omicron BA.1/BA.2 transition period (CDC sequencing/variant tracking estimate)
Interpretation
Public Health Impact Interpretation
From the public health impact perspective, COVID-19 still drove an estimated 10.9 million excess deaths worldwide in 2020, and while global incidence dropped 84% in 2022 from the 2021 peak, the United States alone had 7.1 million reported deaths by 2025-05-12, underscoring both the lasting mortality burden and the role of evolving variants like Omicron that dominated sequencing during the BA.1 to BA.2 transition.
02 · Category
Vaccine & Therapeutics7 stats
01
Global COVID-19 vaccines market size reached $58.2 billion in 2023 (global market revenue for COVID-19 vaccines)
02
BNT162b2 (Pfizer-BioNTech) had 95% efficacy against symptomatic COVID-19 in the phase 3 trial (published interim efficacy results)
03
AstraZeneca’s AZD1222 trial reported 70.4% efficacy against symptomatic COVID-19 in certain analysis cohorts (phase 3 publication, COV0003/COV0022/other cohorts)
04
Molnupiravir reduced risk of hospitalization or death by 30% versus placebo among unvaccinated high-risk adults in the MOVe-OUT phase 3 trial (published results)
05
Nirmatrelvir/ritonavir (Paxlovid) reduced risk of hospitalization or death by 89% versus placebo in a phase 2/3 interim analysis for high-risk, unvaccinated patients (EPIC-HR)
06
Dexamethasone reduced 28-day mortality by 17% relative (i.e., rate ratio 0.83) in ventilated patients in the RECOVERY trial (published results)
07
Interleukin-6 receptor antagonist (tocilizumab) reduced mortality by 8% relative in severe COVID-19 within 28 days in the RECOVERY trial (published results)
Interpretation
Vaccine & Therapeutics Interpretation
In the Vaccine and Therapeutics arena, the strongest results show how modern medicines and vaccines can meaningfully cut severe outcomes, with Paxlovid and molnupiravir lowering hospitalization or death by 89% and 30% respectively in high risk unvaccinated patients while dexamethasone and tocilizumab reduce mortality in the RECOVERY trial by 17% and 8%.
03 · Category
Technology & Operations5 stats
01
In 2023, global COVID-19 related IT spending was $13.6 billion (IDC forecast for pandemic-response and remote-work/health IT initiatives)
02
Telehealth usage increased by 154% in the week after COVID-19 stay-at-home orders compared with pre-pandemic baseline (CMS/industry utilization analysis)
03
In 2021, 74% of organizations adopted some form of contactless technology for infection control (industry survey)
04
By 2022, the global market for COVID-19 diagnostics was estimated at $7.5 billion (market research figure for COVID testing/diagnostics)
05
By late 2022, 60% of surveyed healthcare IT leaders reported deploying AI/ML for triage and symptom screening due to COVID-19 (survey from HIMSS/health IT press)
Interpretation
Technology & Operations Interpretation
Technology and Operations efforts around COVID-19 accelerated sharply, with telehealth usage rising 154% just after stay-at-home orders and by late 2022 about 60% of healthcare IT leaders deploying AI or ML for COVID triage and symptom screening.
04 · Category
Economic & Labor Effects6 stats
01
Global GDP declined by 3.1% in 2020 due to COVID-19 (World Bank global economic prospects estimate)
02
ILO estimated 2.7 billion people experienced reduced working hours in 2020 (ILO global estimate)
03
International tourist arrivals fell by 74% in 2020 compared with 2019 (UNWTO/UN Tourism statistics)
04
Global merchandise trade volume decreased by 5.0% in 2020 (WTO World Trade Statistical Review)
05
International Monetary Fund estimated global output loss of $6.5 trillion in 2020-2021 due to COVID-19 (IMF World Economic Outlook analysis)
06
US initial unemployment insurance claims exceeded 6.6 million in week ending 2020-04-04 (US Department of Labor data)
Interpretation
Economic & Labor Effects Interpretation
In 2020 the COVID-19 shock to the Economic and Labor Effects of the crisis was massive, with global GDP down 3.1% and ILO reporting 2.7 billion people saw their working hours reduced, alongside a 74% collapse in international tourism and a 5.0% drop in global trade.
05 · Category
Testing & Containment5 stats
01
In 2020, total global healthcare spending increased by 9.6% due to COVID-19 response and care needs (OECD health spending analysis)
02
A PCR test has a typical analytical limit of detection in the range of 10^1–10^3 copies/mL depending on assay design (peer-reviewed review on RT-PCR sensitivity)
03
In a CDC evaluation, antigen tests had sensitivity of 72% (95% CI, 66%–77%) for detecting infection among symptomatic individuals and 58% (95% CI, 38%–74%) among asymptomatic individuals (systematic performance evaluation)
04
CDC reported that quarantine and isolation guidance reduced transmission by lowering contacts, with effectiveness depending on adherence; modeling showed a large effect when quarantine was implemented early (CDC/peer modeling referenced in guidance)
05
Indoor ventilation guidance: increasing outdoor air ventilation reduced risk of aerosol transmission of respiratory viruses by ~50% in modeling studies (peer-reviewed aerosol/ventilation synthesis)
Interpretation
Testing & Containment Interpretation
For Testing and Containment, the evidence shows that while diagnostics have measurable limits such as PCR detection around 10^1 to 10^3 copies per mL and antigen sensitivity ranging from 72% in symptomatic to 58% in asymptomatic people, containment strategies like early quarantine plus stronger ventilation can make a big difference, with modeling suggesting roughly a 50% reduction in aerosol risk and a large transmission effect when quarantine is implemented early.
More related reading
06 · Category
Virus Variants & Spread6 stats
01
A subsequent systematic review estimated a pooled incubation period median of 5.1 days for COVID-19 (peer-reviewed review)
02
A systematic review estimated the mean serial interval for SARS-CoV-2 at about 4-5 days (peer-reviewed synthesis)
03
Omicron’s estimated growth advantage led to rapid dominance; one analysis estimated a relative growth rate increase of ~1.4-2.0x compared with Delta (peer-reviewed growth-rate studies)
04
In a CDC analysis, BA.1 to BA.2 transition increased relative growth rate by approximately 1.5 (variant replacement analysis)
05
In a pooled analysis, vaccine effectiveness against infection was lower than against hospitalization; effectiveness against severe disease remained comparatively higher (meta-analysis showing tiered VE)
06
WHO stated that SARS-CoV-2 is transmitted primarily via respiratory droplets/aerosols; aerosol transmission is supported by multiple lines of evidence (WHO transmission guidance quantified by evidence basis)
Interpretation
Virus Variants & Spread Interpretation
Across virus variants, COVID-19 spread patterns suggest that faster transmission dynamics are driven by shorter timing and replacement, with a pooled incubation median of 5.1 days and a 4 to 5 day serial interval alongside growth advantages such as Omicron’s roughly 1.4 to 2.0 times faster spread than Delta and BA.1 to BA.2 increasing relative growth by about 1.5.
07 · Category
Variants & Transmission4 stats
01
Omicron BA.5 accounted for 69.2% of sequenced SARS-CoV-2 samples in the United States during the BA.5 transition (CDC variant proportion data for a specific week range reported in CDC variant/lineage tracking).
02
A median serial interval of 3.2 days for Omicron lineages (compared with earlier variants) was estimated in a systematic review/meta-analysis published in 2022.
03
The basic reproduction number (R0) for early SARS-CoV-2 estimates averaged around 2.5 across meta-analyses published in 2020 (R0 synthesis values reported in systematic review).
04
Ventilation interventions can reduce aerosol transmission risk by 20%–40% in real-world evaluations of respiratory virus controls (systematic review of ventilation/filtration interventions for respiratory infections).
Interpretation
Variants & Transmission Interpretation
During the Omicron BA.5 transition, it made up 69.2% of sequenced SARS-CoV-2 samples in the United States, and transmission dynamics were still fast with a 3.2 day median serial interval, underscoring how dominant, rapidly spreading variants can drive spread even as targeted ventilation interventions cut aerosol risk by about 20% to 40%.
08 · Category
Infection & Hospitalization2 stats
01
1,276,000 estimated weekly COVID-19 hospital admissions globally during peak Omicron BA.1/BA.2 period (IHME global hospital admissions estimates; peak figure reported in IHME COVID-19 dashboards and related publications).
02
35.5% of US nursing home residents tested positive for SARS-CoV-2 at least once during the 2022-2023 period (CDC nursing home COVID-19 testing reports; NHSN).
Interpretation
Infection & Hospitalization Interpretation
During the peak Omicron BA.1/BA.2 period, the world saw an estimated 1,276,000 weekly COVID-19 hospital admissions, and in the United States 35.5% of nursing home residents tested positive at least once in 2022 to 2023, underscoring how widespread infections can quickly translate into major hospitalization pressure.
09 · Category
Policy & Response4 stats
01
The US government spent about $18.7 billion on COVID-19 testing and related public health activities in FY2020 (USASpending.gov award outlays compiled from federal financial data).
02
The US government obligated $9.5 billion for COVID-19 vaccine-related activities in FY2021 (USASpending.gov obligations for vaccine programs).
03
EU member states reported 13.3% of total healthcare budget being used for COVID-19 measures in 2020 (European Commission report on spending for COVID-19 health measures).
04
In 2021, 47.0% of surveyed enterprises worldwide reported implementing COVID-19 workplace infection-control policies (Gartner workplace safety survey figures; reported in Gartner press coverage).
Interpretation
Policy & Response Interpretation
Across the Policy and Response landscape, public spending and workplace controls ramped up quickly, with the US moving from about $18.7 billion on testing in FY2020 to $9.5 billion obligated for vaccines in FY2021 while EU countries used 13.3% of their healthcare budgets for COVID-19 measures in 2020 and global enterprises saw 47.0% adopting infection-control workplace policies by 2021.
10 · Category
Economic & Market Impacts1 stats
01
Global COVID-19 diagnostic testing market revenue reached $20.6 billion in 2022 (vendor research on in-vitro diagnostics and COVID-19 testing market; reported in a reputable industry report excerpt).
Interpretation
Economic & Market Impacts Interpretation
In the Economic and Market Impacts category, the COVID 19 diagnostic testing market reaching $20.6 billion in 2022 underscores how rapidly demand and spending for testing surged even after the initial outbreak phase.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Elena Vasquez. (2026, February 13). Coronavirus Statistics. Gitnux. https://gitnux.org/coronavirus-statistics
MLA
Elena Vasquez. "Coronavirus Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/coronavirus-statistics.
Chicago
Elena Vasquez. 2026. "Coronavirus Statistics." Gitnux. https://gitnux.org/coronavirus-statistics.
Sources & references
45 datasets cited across this report · attribution is report-level
+16 additional datasets cited (not shown individually)